This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

Some of the best links we picked up around the internet

Just as the summer was creeping in, we hosted our most popular CMN webinar to date. The topic was CRISPR Off-Targets with speakers from academia and a...

Editing a single nucleotide in the largest human gene is sufficient to restore dystrophin production and myocyte function in Duchenne muscular...

β-Thalassemia is caused in part by a mutated β-globin gene, so researchers developed a way to replace the entire mutated gene with a healthy version...

Researchers at University of Freiburg in Germany have developed the first assay to identify and quantify unintended chromosomal rearrangements at on-...

Erik Sontheimer, Professor and Vice Chair at the RNA Therapeutics Institute and at the University of Massachusetts Medical School talks to CRISPR...

CRISPR-Cas is seen as the holy grail in medicine for rare and incurable genetic diseases. In this piece, we take a look at what CRISPR can do for...